Laura Fachal

Hinxton, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications

Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease.

Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease.

Journal: The New England journal of medicine
Published: June 10, 2026

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.

Journal: medRxiv : the preprint server for health sciences
Published: May 25, 2026

Neutralising autoantibodies against IL-10 and HLA-DRB1*01:03 in paediatric patients with inflammatory bowel disease.

Neutralising autoantibodies against IL-10 and HLA-DRB1*01:03 in paediatric patients with inflammatory bowel disease.

Journal: Gut
Published: May 05, 2026

Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort.

Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort.

Journal: Clinical and translational radiation oncology
Published: April 17, 2026

HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype-phenotype association study.

HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype-phenotype association study.

Journal: The lancet. Gastroenterology & hepatology
Published: February 20, 2026

A genome-wide association study on radiation induced fibrosis in breast cancer patients.

A genome-wide association study on radiation induced fibrosis in breast cancer patients.

Journal: Clinical and translational radiation oncology
Published: February 11, 2026

Cell-type-resolved genetic regulatory variation shapes inflammatory bowel disease risk.

Cell-type-resolved genetic regulatory variation shapes inflammatory bowel disease risk.

Journal: medRxiv : the preprint server for health sciences
Published: July 16, 2025

Cell-type-resolved genetic variation shapes inflammatory bowel disease risk.

Cell-type-resolved genetic variation shapes inflammatory bowel disease risk.

Journal: Nature
Published: June 24, 2025

Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients.

Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients.

Journal: Nature communications
Published: April 30, 2025

Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource.

Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource.

Journal: Alimentary pharmacology & therapeutics
Published: March 31, 2025

Cystic fibrosis risk variants confer protection against inflammatory bowel disease.

Cystic fibrosis risk variants confer protection against inflammatory bowel disease.

Journal: Cell genomics
Published: December 16, 2024

Cystic fibrosis risk variants confer protection against inflammatory bowel disease.

Cystic fibrosis risk variants confer protection against inflammatory bowel disease.

Journal: medRxiv : the preprint server for health sciences
Published: December 16, 2024
Showing 1-12 of 72

Last Updated: 09/26/2026